Co-Authors
This is a "connection" page, showing publications co-authored by Marek Jutel and Oliver Pfaar.
Connection Strength
2.844
-
Technical standards in allergen exposure chambers worldwide - an EAACI Task Force Report. Allergy. 2021 12; 76(12):3589-3612.
Score: 0.245
-
COVID-19 pandemic and allergen immunotherapy-an EAACI survey. Allergy. 2021 11; 76(11):3504-3516.
Score: 0.241
-
COVID-19 pandemic: Practical considerations on the organization of an allergy clinic-An EAACI/ARIA Position Paper. Allergy. 2021 03; 76(3):648-676.
Score: 0.233
-
Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic: Position paper of Ärzteverband Deutscher Allergologen (AeDA)A, Deutsche Gesellschaft für Allergologie und Klinische Immunologie (DGAKI)B, Gesellschaft für Pädiatrische Allergologie und Umweltmedizin (GPA)C, Österreichische Gesellschaft für Allergologie und Immunologie (ÖGAI)D, Luxemburgische Gesellschaft für Allergologie und Immunologie (LGAI)E, Österreichische Gesellschaft für Pneumologie (ÖGP)F in co-operation with the German, Austrian, and Swiss ARIA groupsG, and the European Academy of Allergy and Clinical Immunology (EAACI)H. Allergol Select. 2020; 4:53-68.
Score: 0.225
-
[Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI-AeDA-GPA-DGAKI Position Paper (Pocket-Guide)]. Laryngorhinootologie. 2020 10; 99(10):676-679.
Score: 0.225
-
Allergen exposure chambers: harmonizing current concepts and projecting the needs for the future - an EAACI Position Paper. Allergy. 2017 Jul; 72(7):1035-1042.
Score: 0.179
-
International Consensus on Allergen Immunotherapy II: Mechanisms, standardization, and pharmacoeconomics. J Allergy Clin Immunol. 2016 Feb; 137(2):358-68.
Score: 0.164
-
Management of anaphylaxis due to COVID-19 vaccines in the elderly. Allergy. 2021 10; 76(10):2952-2964.
Score: 0.061
-
Differentiation of COVID-19 signs and symptoms from allergic rhinitis and common cold: An ARIA-EAACI-GA2 LEN consensus. Allergy. 2021 08; 76(8):2354-2366.
Score: 0.059
-
Potential Interplay between Nrf2, TRPA1, and TRPV1 in Nutrients for the Control of COVID-19. Int Arch Allergy Immunol. 2021; 182(4):324-338.
Score: 0.058
-
Spices to Control COVID-19 Symptoms: Yes, but Not Only…. Int Arch Allergy Immunol. 2021; 182(6):489-495.
Score: 0.057
-
Considerations on biologicals for patients with allergic disease in times of the COVID-19 pandemic: An EAACI statement. Allergy. 2020 11; 75(11):2764-2774.
Score: 0.057
-
Correction to: Is diet partly responsible for differences in COVID-19 death rates between and within countries? Clin Transl Allergy. 2020; 10:44.
Score: 0.057
-
Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIA-EAACI statement. Allergy. 2020 10; 75(10):2440-2444.
Score: 0.057
-
ARIA-EAACI statement on asthma and COVID-19 (June 2, 2020). Allergy. 2021 03; 76(3):689-697.
Score: 0.056
-
A compendium answering 150 questions on COVID-19 and SARS-CoV-2. Allergy. 2020 10; 75(10):2503-2541.
Score: 0.056
-
Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement. Allergy. 2020 07; 75(7):1546-1554.
Score: 0.056
-
Allergen immunotherapy in the current COVID-19 pandemic: A position paper of AeDA, ARIA, EAACI, DGAKI and GPA: Position paper of the German ARIA GroupA in cooperation with the Austrian ARIA GroupB, the Swiss ARIA GroupC, German Society for Applied Allergology (AEDA)D, German Society for Allergology and Clinical Immunology (DGAKI)E, Society for Pediatric Allergology (GPA)F in cooperation with AG Clinical Immunology, Allergology and Environmental Medicine of the DGHNO-KHCG and the European Academy of Allergy and Clinical Immunology (EAACI)H. Allergol Select. 2020; 4:44-52.
Score: 0.055
-
Is diet partly responsible for differences in COVID-19 death rates between and within countries? Clin Transl Allergy. 2020; 10:16.
Score: 0.055
-
Provocative proposal for a revised nomenclature for allergy and other hypersensitivity diseases. Allergy. 2018 10; 73(10):1939-1940.
Score: 0.049
-
EAACI guidelines on allergen immunotherapy: Executive statement. Allergy. 2018 04; 73(4):739-743.
Score: 0.048
-
Allergen manufacturing and quality aspects for allergen immunotherapy in Europe and the United States: An analysis from the EAACI AIT Guidelines Project. Allergy. 2018 04; 73(4):816-826.
Score: 0.047
-
Challenges in the implementation of the EAACI AIT guidelines: A situational analysis of current provision of allergen immunotherapy. Allergy. 2018 04; 73(4):827-836.
Score: 0.047
-
EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy. Allergy. 2018 04; 73(4):744-764.
Score: 0.047
-
EAACI Guidelines on allergen immunotherapy: IgE-mediated food allergy. Allergy. 2018 04; 73(4):799-815.
Score: 0.047
-
EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis. Allergy. 2018 04; 73(4):765-798.
Score: 0.046
-
EAACI guidelines on allergen immunotherapy: Prevention of allergy. Pediatr Allergy Immunol. 2017 Dec; 28(8):728-745.
Score: 0.046
-
Peak nasal inspiratory flow as outcome for provocation studies in allergen exposure chambers: a GA2LEN study. Clin Transl Allergy. 2017; 7:33.
Score: 0.046
-
Erratum to: Allergen immunotherapy for allergic asthma: protocol for a systematic review. Clin Transl Allergy. 2017; 7:32.
Score: 0.046
-
Challenges in the implementation of EAACI guidelines on allergen immunotherapy: A global perspective on the regulation of allergen products. Allergy. 2018 Jan; 73(1):64-76.
Score: 0.046
-
Allergen immunotherapy for allergic asthma: a systematic overview of systematic reviews. Clin Transl Allergy. 2017; 7:25.
Score: 0.045
-
Allergen immunotherapy for allergic asthma: A systematic review and meta-analysis. Allergy. 2017 Dec; 72(12):1825-1848.
Score: 0.045
-
ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. Clin Transl Allergy. 2016; 6:47.
Score: 0.044